Ahmed Enayetallah
With a robust background in clinical research and deep expertise in drug development, Ahmed's career spans several high-profile roles across leading pharmaceutical & biotechnology companies such as Amgen, Biogen and Alexion. Ahmed earned his medical degree from the University of Cairo and completed his Ph.D. in Pharmacology and Toxicology at the University of Connecticut. His early career included significant contributions, where he led efforts in personalized medicine and championed precision medicine initiatives leveraging earlier AI platforms. Later in his career, he led and oversaw multiple successful clinical programs that brought novel therapies to patients with high unmet medical needs. In his role prior to joining Dompé, he led the development organization at BlueRock Therapeutics and drove the company’s mission to harness the power of cell therapy, navigating through mostly uncharted territories. Ahmed’s leadership is characterized by his strategic vision and commitment to advancing medical science through innovative research and development. His work reflects a dedication to improving patient lives and advancing the frontiers of medical research and therapeutics.